- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01980680
The Exogenous Progesterone Free Luteal Phase After GnRHa Trigger - a Pilot Study in Normo-responder IVF Patients (GnRHa trigger)
December 16, 2020 updated by: Peter Humaidan
The Exogenous Progesterone Free Luteal Phase After GnRHa Trigger - a Randomized Controlled Pilot Study in Normo-responder IVF Patients
After hCG trigger a large amount of exogenous progesterone is used for luteal phase support in many countries until 10th week of gestation.
Instead we suggest the use of two small doses of hCG after the trigger during the early luteal phase after GnRHa trigger, promoting the endogenous progesterone production from the corpora lutea (CL).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
50
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Skive, Denmark, 7800
- The Fertility Clinic, Regional Hospital of Skive
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 40 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Age between 20 and 40
- Normal menstrual cycles: 25-34 days
- Oligomenorrhea/amenorrhea or polycystic syndrome (defined according to the Rotterdam criteria 2004)
- BMI >18 and <35 kg/m2
Exclusion Criteria:
- Patients with >14 follicles on day of trigger
- Previous hyperresponse with OHSS development
- Previous low response (less than 3 oocytes on a high dose of FSH stimulation)
- Endocrine disorders
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Agonist trigger
Agonist trigger Buserelin 0,5 mg and Pregnyl (hCG)
|
|
Active Comparator: hCG
hCG trigger Pregnyl (hCG) and Progesterone and Estradiol
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Ongoing pregnancy rate per patient
Time Frame: 10th week of gestation.
|
10th week of gestation.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2014
Primary Completion (Actual)
September 1, 2019
Study Completion (Actual)
May 1, 2020
Study Registration Dates
First Submitted
October 28, 2013
First Submitted That Met QC Criteria
November 4, 2013
First Posted (Estimate)
November 11, 2013
Study Record Updates
Last Update Posted (Actual)
December 17, 2020
Last Update Submitted That Met QC Criteria
December 16, 2020
Last Verified
December 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Agonist5
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infertility
-
Assuta Hospital SystemsMaccabi Healthcare Services, IsraelCompletedInfertility, Female Infertility, Male InfertilityIsrael
-
Radboud University Medical CenterZonMw: The Netherlands Organisation for Health Research and DevelopmentCompletedPregnancy | Male Infertility | Female InfertilityNetherlands
-
Sapientiae InstituteTerminated
-
Esraa Gamal AhmedAin Shams Maternity HospitalUnknownUnexplained Female Infertility
-
King's College LondonNot yet recruitingInfertility | Infertility, Female | Infertility Unexplained | Infertility of Tubal Origin
-
Gazi UniversityCompletedMale Infertility | Unexplained Infertility
-
University of WashingtonEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedMale Infertility, AzoospermiaUnited States
-
Wake Forest University Health SciencesWithdrawnUterine Diseases | Endometriosis | Infertility Unexplained | Endometrial Diseases | Infertility; Female, NonimplantationUnited States
-
Pacific Fertility CenterTerminatedPrimary Female Infertility | Secondary Female Infertility
-
Istanbul University - Cerrahpasa (IUC)RecruitingInfertility | Sexual Dysfunction | Infertility, Male | Nurse's Role | Sexuality | Infertility; FemaleTurkey
Clinical Trials on hCG
-
Royan InstituteCompletedInfertilityIran, Islamic Republic of
-
Wael Elbanna ClinicNational Research Centre, EgyptRecruitingStudy to Assess the Effect of Intrauterine Adminstration of HCG Versus Endometrial Injury by PipelleFemale InfertilityEgypt
-
Sohag UniversityRecruitingWoman With Tubal Ectopic PregnancyEgypt
-
Assaf-Harofeh Medical CenterUnknown
-
Assaf-Harofeh Medical CenterCompletedRetained Products of ConceptionIsrael
-
AZ Jan Palfijn GentOnze Lieve Vrouw HospitalCompletedInfertility | PCOSBelgium
-
IBSA Institut Biochimique SACompleted
-
Aristotle University Of ThessalonikiCompleted